Adaptive T cell immunotherapy in cancer |
| |
Authors: | Ti Dongdong Bai Miaomiao Li Xiaolei Wei Jianshu Chen Deyun Wu Zhiqiang Wang Yao Han Weidong |
| |
Affiliation: | 1.Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China ; |
| |
Abstract: | Impaired tumor-specific effector T cells contribute to tumor progression and unfavorable clinical outcomes. As a compensatory T cell-dependent cancer immunoediting strategy, adoptive T cell therapy(ACT) has achieved encouraging therapeutic results,and this strategy is now on the center stage of cancer treatment and research. ACT involves the ex vivo stimulation and expansion of tumor-infiltrating lymphocytes(TILs) with inherent tumor reactivity or T cells that have been genetically modified to express the cognate chimeric antigen receptor or T cell receptor(CAR/TCR), followed by the passive transfer of these cells into a lymphodepleted host. Primed T cells must provide highly efficient and long-lasting immune defense against transformed cells during ACT. Anin-depth understanding of the basic mechanisms of these living drugs can help us improve upon current strategies and design better next-generation T cell-based immunotherapies. From this perspective, we provide an overview of current developments in different ACT strategies, with a focus on frontier clinical trials that offer a proof of principle. Meanwhile, insights into the determinants of ACT are discussed, which will lead to more rational, potent and widespread applications in the future. |
| |
Keywords: | |
本文献已被 CNKI SpringerLink 等数据库收录! |
|